TriCares GmbH unveiled first-in-human data for its Topaz transcatheter tricuspid valve replacement (TTVR) system at EuroPCR in Paris, with promising results for patients with tricuspid regurgitation (TR).
Presented by Julien Dreyfus, MD, PhD, the study highlighted:
- Significant elimination of TR in all 20 patients
- No need for permanent pacemakers
- Average procedure time: 35 minutes
The Topaz TTVR features a two-stent valve prosthesis delivered through the femoral or jugular vein. Though still investigational, it’s already been used in 60 procedures globally.
TriCares CEO Ahmed Elmouelhi said these early outcomes validate continued trials in Europe and the U.S., aiming to refine the technique and expand use.
Follow MEDWIRE.AI for updates on structural heart innovations.
